Alert detail
FDA Approval: AMBELVIST (GADOQUATRANE) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA219627Specialty: RadiologyAdded: 6/18/2026Effective: 2026-06-12billing update
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.